MedTrace Logo

Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia

NCT05098249 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2023-05-24

No results posted yet for this study

Summary

This is a confirmatory trial to establish superior serum phosphate stability associated with use of Phoscap® compared with placebo as a supplement for treatment of iron deficiency or iron deficiency anemia with Ferinject® before elective surgery.

Conditions

  • Anemia
  • Iron-deficiency
  • Hypophosphatemia

Interventions

DRUG

Verum

The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.

DRUG

Placebo

The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Donat R. Spahn

    lead OTHER

Principal Investigators

  • Donat R Spahn, Prof. Dr. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2023-05-09
Completion
2023-05-23

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05098249 on ClinicalTrials.gov